These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38710274)

  • 1. BDTX-189, a novel tyrosine kinase inhibitor, inhibits cell activity via ERK and AKT pathways in the EGFR C797S triple mutant cells.
    Wang R; Cui W; Li L; Wei X; Chu C; Zhang G; Liu C; Xu H; Liu C; Wang K; Li Y; An L
    Chem Biol Interact; 2024 May; 395():111033. PubMed ID: 38710274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
    Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.
    Liu Y; Lai M; Li S; Wang Y; Feng F; Zhang T; Tong L; Zhang M; Chen H; Chen Y; Song P; Li Y; Bai G; Ning Y; Tang H; Fang Y; Chen Y; Lu X; Geng M; Ding K; Yu K; Xie H; Ding J
    Cancer Sci; 2022 Feb; 113(2):709-720. PubMed ID: 34855271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation.
    Su Z; Yang T; Wang J; Lai M; Tong L; Wumaier G; Chen Z; Li S; Li H; Xie H; Zhao Z
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127327. PubMed ID: 32631532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation.
    Yao H; Ren Y; Wu F; Liu J; Li J; Cao L; Yan M; Li X
    Eur J Med Chem; 2024 Sep; 275():116590. PubMed ID: 38908104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the Overcoming EGFR
    Zhang X; He J; Xu S; Fu L; Zheng P; Xu S; Pan Q; Zhu W
    ChemMedChem; 2024 May; 19(9):e202300634. PubMed ID: 38351876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.
    Zhu Y; Ye X; Wu Y; Shen H; Cai Z; Xia F; Min W; Hou Y; Wang L; Wang X; Xiao Y; Yang P
    J Med Chem; 2024 May; 67(9):7283-7300. PubMed ID: 38676656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
    Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
    Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin.
    Huang KY; Wang TH; Chen CC; Leu YL; Li HJ; Jhong CL; Chen CY
    Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
    Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells.
    Li L; Liu C; Wang R; Yang X; Wei X; Chu C; Zhang G; Liu C; Cui W; Xu H; Wang K; An L; Li X
    Sci Rep; 2024 Oct; 14(1):22895. PubMed ID: 39358400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Zhang M; Wang Y; Wang J; Liu Z; Shi J; Li M; Zhu Y; Wang S
    Chem Pharm Bull (Tokyo); 2020; 68(10):971-980. PubMed ID: 32999149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
    Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
    Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights.
    Suriya U; Mahalapbutr P; Wimonsong W; Yotphan S; Choowongkomon K; Rungrotmongkol T
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36558033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor.
    Nishiya N; Oku Y; Ishikawa C; Fukuda T; Dan S; Mashima T; Ushijima M; Furukawa Y; Sasaki Y; Otsu K; Sakyo T; Abe M; Yonezawa H; Ishibashi F; Matsuura M; Tomida A; Seimiya H; Yamori T; Iwao M; Uehara Y
    Cancer Sci; 2021 May; 112(5):1963-1974. PubMed ID: 33544933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a potent, selective, and orally available EGFR C797S mutant inhibitor (DS06652923) with in vivo antitumor activity.
    Kageji H; Momose T; Ebisawa M; Nakazawa Y; Okada H; Togashi N; Nagamoto Y; Obuchi W; Yasumatsu I; Kihara K; Hiramoto K; Minami M; Kasanuki N; Isoyama T; Naito H; Tanaka N
    Bioorg Med Chem; 2024 Sep; 111():117862. PubMed ID: 39111073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
    Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
    J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer.
    Park H; Jung HY; Kim K; Kim M; Hong S
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation.
    Zuo Y; Long Z; Li R; Le Y; Zhang S; He H; Yan L
    Eur J Med Chem; 2024 Feb; 265():116106. PubMed ID: 38169271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S.
    Wang TH; Leu YL; Chen CC; Li HJ; Yang SC; Huang KY; Chen CY
    Phytother Res; 2022 May; 36(5):2116-2126. PubMed ID: 35229911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.